Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Palatin Technologies Inc PTN

Healthcare Biotechnology
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus... see more

Recent & Breaking News (NYSEAM:PTN)

Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial

PR Newswire October 28, 2013

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results

PR Newswire September 30, 2013

Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results

PR Newswire September 25, 2013

Faruqi & Faruqi, LLP Launches An Investigation Against Palatin Technologies Inc. (PTN) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Business Wire June 4, 2013

Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction

PR Newswire May 14, 2013

Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013

PR Newswire May 8, 2013

Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction

PR Newswire May 2, 2013

Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides

PR Newswire March 19, 2013

Palatin Technologies To Present At The 25th Annual ROTH Conference

PR Newswire March 15, 2013

Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference

PR Newswire March 4, 2013

Palatin Technologies Presents Positive Data for Bremelanotide in Female Sexual Dysfunction

PR Newswire March 1, 2013

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013

PR Newswire February 14, 2013

Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013

PR Newswire February 8, 2013

Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference

PR Newswire February 7, 2013

Palatin Technologies Receives $1.75 Million from Sale Of New Jersey State Tax Credits

PR Newswire January 3, 2013